10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders intended to buy $40 million on the IPO (40% of the...read more
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, announced terms for its IPO on Friday.
The Cambridge, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14...read more
US IPO Weekly Recap: Biotechs boom in a 13-deal torrent
10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Magenta Therapeutics prices $100 million IPO at $15 midpoint
Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders intended to buy $40 million on the IPO (40% of the...read more
US IPO Week Ahead: Health care deals lead 11-IPO week
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Stem cell biotech Magenta Therapeutics sets terms for $100 million IPO
Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14...read more